comparemela.com

Page 2 - Andrew Farnum News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Variant Bio Turns Focus from Identifying Genomic Variants to Drug Discovery

To date, the company has built a foundation of more than 20 genomic research partnerships across six continents.

Variant Bio Turns Toward Discovery of Novel Medicines, Marking a New Chapter of Growth for the Compa

David Moller joins as Chief Scientific Officer and Steve Bryant as Chief Business Officer, adding deep expertise to executive teamSEATTLE (BUSINESS WIRE) Variant Bio, a genomics-driven drug discovery company, is transitioning from a company that focused on identifying genomic variants that uncover the basis of dis.

vimarsana © 2020. All Rights Reserved.